Caxton Associates (UK)’s Insmed INSM Stock Holding History

Caxton Associates (UK)’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,785	Closed	-$441K	–	791
2025 Q1	$441K	Buy	+5,785	New	+$443K	0.02%	523

Other funds holding INSM

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caxton Associates (UK)'s INSM Position: Q2 2025 in Review

Caxton Associates (UK) sold out of Insmed (INSM) in Q2 2025, closing a stake of 5,785 shares — an estimated $441K sold.

Caxton Associates (UK) first reported a position in INSM in Q1 2025 and held it in 1 quarter. The position peaked at $441K in Q1 2025. 516 funds tracked by Wall St. Rank hold INSM as of Q2 2025.

Caxton Associates (UK) reported no remaining Insmed position as of Q2 2025 after selling out during the quarter.
Caxton Associates (UK) sold 5,785 Insmed shares in Q2 2025, an estimated $441K.
Caxton Associates (UK) first reported a position in Insmed in Q1 2025 and held it in 1 quarter.
Caxton Associates (UK)'s Insmed position peaked at $441K in Q1 2025.
516 funds tracked by Wall St. Rank held Insmed as of Q2 2025.

Based on Caxton Associates (UK)'s 13F filing for Q2 2025, filed 15 Aug 2025.